Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Philanthropy at Mayo ClinicYour support accelerates powerful innovations in patient care, research and education. Give today.
Search Results 41-50 of 62 for Oral
Because these small drug-like compounds are not degraded in the gastrointestinal tract, they carry potential as oral agents for the treatment of both Graves' hyperthyroidism and GO.
Sign up Related Content Article The gaining popularity of oral appliances Article Getting to the heart of sleep Article The emerging option of upper airway stimulation therapy
Outpatient treatment, when possible, is preferred, but a lack of response to oral antibiotic therapy often necessitates hospital admission for provision of IV antibiotics and more intense adjunctive therapies.
Reversibility is maintained with oral immunosuppressants such as prednisone, azathioprine, mycophenolate, methotrexate or rituximab — at the minimum effective dosage, to minimize side effects.
Lifelong treatment with warfarin blood-thinning therapy or a direct oral anticoagulant is typically effective in preventing clot formation that leads to stroke.
If symptoms and objective testing show improvement, the next step is to maintain that level of reversibility with the minimum effective dosage of maintenance oral immunosuppressants.
The effectiveness of the new oral anticoagulants in preventing stroke in patients with PFO has not been evaluated.
Sign up Related Content Video Mesalamine dose may lower marker of bowel inflammation Article Tofacitinib is first oral medication approved for use in treating moderate to severe ulcerative colitis Article Research establishes strong ...
., transplant hepatologist and associate professor of medicine at Mayo Clinic's campus in Florida, talks about his latest study - how two new oral medications, used post-liver transplant, are safe and beneficial in the treatment of H...
Endoscopic response overall 63.1% of patients who were managed endoscopically achieved complete success without surgery. 87.9% of patients who were managed endoscopically did not require surgery for at least 30 days. 35.9% of patients who were manage...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.